|
|
News Breaks | | | | September 10, 2012 | | 07:48 EDT |  | CRIS | Curis valuation compelling ahead of pipeline catalysts, says Piper Jaffray
Piper Jaffray believes the launch of Erivedge is off to a solid start and views shares of Curis as compelling ahead of several pipeline drivers. The firm reiterates an Overweight rating on the stock with a $7 price target. | |
|
News For CRIS From The Last 14 Days Check below for free stories on CRIS the last two weeks. |
|
|
| May 10, 2013 | | 07:04 EDT |  | CRIS | Curis announces approval of Erivedge in Australia
Curis announced that Erivedge was approved for marketing registration by Australia's Therapeutic Goods Administration for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate. Erivedge is the first licensed treatment in Australia for patients with advanced basal cell carcinoma, a rare form of skin cancer which can be disfiguring, debilitating and even fatal. Curis earned a $4M milestone payment as a result of the TGA's approval of Erivedge and Curis is also entitled to receive royalties on Roche's future net sales of Erivedge in Australia. | |
|
|
|
|
|
|
